neuehealth CFO Jay Matushak sells $36,430 in inventory

MINNEAPOLIS—Jay Matushak, Chief Monetary Officer of NeueHealth, Inc. (NASDAQ:NEUE), not too long ago offered shares of the corporate’s frequent inventory, in response to a submitting with the Securities and Trade Fee. The transaction, dated January 6, concerned the sale of 4,970 shares at a weighted common value of $7.33 per share, totaling roughly $36,430.

The shares had been offered to cowl tax withholding obligations upon the vesting of restricted inventory models, as famous within the submitting. These transactions weren’t discretionary on the a part of Matushak. Following the sale, Matushak holds 17,747 shares of NeueHealth inventory.

The shares had been offered in a number of transactions at costs starting from $7.18 to $7.50 per share. Matushak has dedicated to offering full particulars of the transactions upon request. The inventory has proven robust momentum, posting constructive returns over each one-month and three-month intervals, regardless of working with average debt ranges.

In different latest information, RBC Capital has revised its outlook on shares of NeueHealth, lowering the worth goal from $8.00 to $7.00. This adjustment follows the corporate’s third-quarter outcomes, which, regardless of exceeding expectations, revealed a year-over-year income decline of 9.01%. Regardless of the drop in income, the corporate’s administration group has confirmed that their steering stays unchanged.

RBC Capital’s choice to decrease the worth goal is a mirrored image of an replace to their valuation mannequin for the upcoming yr, making an allowance for the strong third-quarter outcomes and aligning the valuation with the forthcoming fiscal interval. Regardless of the lowered value goal, RBC Capital has maintained a Sector Carry out score on the corporate’s inventory, suggesting a impartial stance on the inventory’s anticipated efficiency relative to different firms in the identical business.

These latest developments present buyers with a revised benchmark for NeueHealth’s market valuation. In response to InvestingPro evaluation, the inventory seems undervalued at present ranges, providing potential insights for these contemplating NeueHealth for his or her portfolios.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.